ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Nothing like a bit of fear to promote PMN310 science

<< Previous

Bullboard Posts

Next >>

Comment by M101on Apr 16, 2023 6:44pm

65 Views

Post# 35397604

RE:RE:RE:RE:Nothing like a bit of fear to promote PMN310 science

Irrational exhuberance, the propellant for a moon shot is still efficacy. But at least we could get off the ground if managment would do a better job of promoting what next-generation means.
It's not like communications tech where you can just google it, you can't just say the phrase here and then leave it to big pharma's spin machine, they're the enemy.

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition